News Updates

More Articles Back to Article

Sandoz invests $400M for new Slovenia biologics plant

Sandoz announced it will construct a new biologics manufacturing plant at the signing of a Memorandum of Understanding in Slovenia. The project is expected to cost approximately $400 million, and "(t)his investment underscores our ambition to be the sustainable global leader in biosimilars, a segment projected to grow double-digit annually over the next decade," said Sandoz CEO Richard Saynor. Drug Store News (3/14)

Read full article now.

Articles are only one benefit of being a DIA member. Learn more and join today so you don’t miss another article!